周祐吉 博士

研究副技師

中央研究院 生醫轉譯研究中心 RNA技術平台與基因操控核心設施

Office: 轉譯中心 B453 (國家生技研究園區)

Office TEL: (02)7750-5852

Lab TEL: (02)7750-5500#2457

E-mail: chou0315@sinica.edu.tw

 

 

1998 – 2004     博士    國立陽明大學  微生物暨免疫學研究所 (主修：病毒學)

1996 – 1998     碩士    國立陽明大學  微生物暨免疫學研究所 (主修：病毒學)

1992 – 1996     學士    國立臺灣大學  植物病蟲害學系 (主修：微生物學)

 

 

 

2020 – 迄今	特約副研究員	台北榮民總醫院 醫學研究部
2020 – 迄今	委員會委員	中央研究院 生命科學圖書館
2020 – 迄今	研究助技師	中央研究院 生醫轉譯研究中心
2019 – 迄今	核心經理	RNA技術平台與基因操控核心設施
2016 – 2020	研究助技師	中央研究院 基因體研究中心
2015 – 2019	核心經理	標靶式操控基因表達核心設施
2013 – 2015	核心副經理	RNAi核心設施
2005 – 2016	博士後研究	中央研究院 分子生物研究所
2004 – 2005	國防工業訓儲預備軍(士)官

 

 

 

1. 財團法人肝病防治學術基金會 B肝特別獎 (2007)

   研究題目：探討B型肝炎病毒其共價連鎖閉合環型去氧核醣核酸之轉錄效率

2. 財團法人肝病防治學術基金會 優秀論文獎 (2005)

   研究題目：探討乙型轉型成長因子(TGF-β)抑制B型肝炎病毒活性的作用機制

 

 

 

1. Chen LC, Hsieh YL, Tan GYT, Kuo TY, Chou YC, Hsu PH, Hwang-V WW*. Differential effects of SUMO1 and SUMO2 on circadian protein PER2 stability and function. Sci Rep. 11(1): 14431 (2021)
2. Chen YC, Chou YC, Hsieh YT, Kuo PY, Yang ML, Chong HE, Wu CL, Shiau AL, Wang CR*. Targeting Intra-Pulmonary P53-Dependent Long Non-Coding RNA Expression as a Therapeutic Intervention for Systemic Lupus Erythematosus-Associated Diffuse Alveolar Hemorrhage. Int J Mol Sci. 22(13): 6948 (2021)
3. Hsieh MH, Beirag N, Murugaiah V, Chou YC, Kuo WS, Kao HF, Madan T, Kishore U, Wang JY*. Human surfactant protein D binds S1 and receptor binding domain of spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro. Front Immunol. 12: 641360 (2021).
4. Tsai CY, Chou YC, Chen CY, Jan JT, Chang ML, Lu LA, Huang PY, Hsu TT, Hsueh YP*. Sex-biased response to and brain cell infection by SARS-CoV-2 in a highly susceptible human ACE2 transgenic model. BioRxiv (2021)(doi: https://doi.org/10.1101/2021.05.04.441029)
5. Lien CE, Kuo TY, Lin YJ, Lian WC, Lin MY, Liu LTC, Chou YC, Chen C*. Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern. MedRxiv (2021)(doi: https://doi.org/10.1101/2021.03.19.21254000)
6. Lai ZS, Yeh TK, Chou YC, Hsu T, Lu CT, Kung FC, Hsieh MY, Lin CH, Chen CT, Shen CKJ*, Jiaang WT*. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease. Eur J Med Chem. 209: 112938 (2021).
7. Huang KY, Lin MS, Kuo TC, Chen CL, Lin CC, Chou YC, Chao TL, Pang YH, Kao HC, Huang RS, Lin S, Chang SY, Yang PC*. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. EMBO Mol Med. 13(1): e12828 (2021).
8. Huang PH, Tsai HH, Liao BH, Lin YL, Jan JT, Tao MH, Chou YC, Hu CMJ, Chen HW*. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain. Hum Vaccin Immunother. 17(3): 654-655  (2021)
9. Chen YC, Kuo PY, Chou YC, Chong HE, Hsieh YT, Yang ML, Wu CL, Shiau AL*,  Wang CR*. Up-regulated expression of pro-apoptotic long noncoding RNA lincRNA-p21 with enhanced cell apoptosis in lupus nephritis. Int J Mol Sci. 22(1): 301 (2020)
10. Chen CY, Chou YC, Hsueh YP*. SARS-CoV-2 D614 and G614 spike variants impair neuronal synapses and exhibit differential fusion ability. BioRxiv (2020)(doi: https://doi.org/10.1101/2020.12.03.409763)
11. Tan BS, Yang MC, Singh S, Chou YC, Chen HY, Wang MY, Wang YC, Chen RH. LncRNA NORAD is repressed by the YAP pathway and suppresses lung and breast cancer metastasis by sequestering S100P. Oncogene. 38(28): 5612 (2019).
12. Kuo WY, Hsu HJ, Wu CY, Chen HS, Chou YC, Tsou YL, Peng HP, Jian JW, Yu CM, Chiu YK, Chen IC, Tung CP, Hsiao M, Lin CL, Wang YA, Wang AH, Yang AS*. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models. MAbs. 11(1): 153 (2019).
13. Yao WL, Ikeda S, Tsukamoto Y, Shindo K, Otakaki Y, Qin M, Iwasawa Y, Takeuchi F, Kaname Y, Chou YC, Chang C, Watashi K, Wakita T, Noda T, Kato H, Fujita T*. Establishment of a human hepatocellular cell line capable of maintaining long-term replication of hepatitis B virus. Int Immunol. 29(3): 109 (2017).
14. Chao CC, Wu PH, Huang HC, Chung HY, Chou YC, Cai BH, Kannagi R*. Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer. FEBS Lett. 591(13):1902 (2017).
15. Tsai KN, Chong CL, Chou YC, Huang CC, Wang YL, Chen ML, Hsu JC, Wang SW, Chen CH*, Chang C*. Doubly Spliced RNA of Hepatitis B Virus Suppresses Viral mRNA Expression Through TATA-Binding-Protein-Mediated Stress Granule Assembly. J Virol. 89(22):11406 (2015).
16. Chou YC, Chen RL, Lai ZS, Song JS, Chao YS, Shen C-K James*. Pharmacological induction of human fetal globin gene in hydroxyurea-resistant primary adult erythroid cells. Molecular and Cellular Biology. Mol Cell Biol. 35(14): 2541 (2015).
17. Chen YF, Chong CL, Wu YC, Wang YL, Tsai KN, Kuo TM, Hong MH, Hu CP, Chen ML, Chou YC*, Chang C*. Doxorubicin activates hepatitis B virus replication by elevation of p21 (Waf1/Cip1) and C/EBPα expression. PlosONE. 10(6): e0131743 (2015). (as a corresponding author)
18. Wang YL, Liou GG, Lin CH, Chen ML, Kuo TM, Tsai KN, Huang CC, Chen YL, Huang LR, Chou YC*, Chang C*. The inhibitory effect of the hepatitis B virus singly-spliced RNA-encoded p21.5 protein on HBV nucleocapsid formation. PlosONE. 10(3): e0119625 (2015). (as a corresponding author)
19. Chou YC, Lai MMC, Wu YC, Hsu NC, Jeng KS, Su WC*. Variations in genome-wide RNAi screens: lessons from influenza research. Journal of Clinical Bioinformatics. 5: 2 (2015).
20. Chen YJ, Wu SY, Chen CC, Tsao YL, Hsu NC, Chou YC*, Huang HL*. Armillaria mellea component armillarikin induces apoptosis in human leukemia cells.  Journal of Functional Foods. 6:196 (2014). (as a corresponding author)
21. Huang CC, Kuo TM, Yeh CT, Hu CP, Chen YL, Tsai YL, Chen ML, Chou YC*, Chang C*. One single nucleotide difference alters the differential expression of spliced RNAs between HBV genotypes A and D. Virus Res. 174(1-2):18 (2013). (as a corresponding author)
22. Hong MH, Chou YC, Wu YC, Tsai KN, Hu CP, Jeng KS, Chen ML, Chang C*. Transforming growth factor-b1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4a expression. PlosONE. 7(1):e30360 (2012).
23. Chong CL, Chen ML, Wu YC, Tsai KN, Huang CC, Hu CP, Jeng KS, Chou YC*, Chang C*. Dynamics of HBV cccDNA expression and transcription in different cell growth phase. J Biomed Sci. 18:96 (2011). (as a corresponding author)
24. Chen RL, Chou YC, Lan YJ, Huang TS, Shen CK*. Developmental silencing of human zeta-globin gene expression is mediated by the transcriptional repressor RREB1. J Biol Chem. 285(14):10189 (2010).
25. Hou SC, Chan LW, Chou YC, Su CY, Chen X, Shih YL, Tsai PC, Shen CK*, Yan YT*. Ankrd17, an ubiquitously expressed ankyrin factor, is essential for the vascular integrity during embryogenesis. FEBS Lett. 583(17):2765 (2009).
26. Chou YC, Chen ML, Hu CP, Chen YL, Chong CL, Tsai YL, Liu TL, Jeng KS, Chang C*. Transforming growth factor-beta1 suppresses hepatitis B virus replication primarily through transcriptional inhibition of pregenomic RNA. Hepatology. 46(3):672 (2007). (Special Award for Academic Research of Hepatitis B Virus Highlight)
27. Chou YC, Jeng KS, Chen ML, Liu HH, Liu TL, Chen YL, Liu YC, Hu CP, Chang C*. Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol. 79(3):1813 (2005). (Outstanding Academic Paper Award Highlight)

 

 

1. RREB1 as A Target for Therapy of Thalassemias and Sickle Cell Anemia.
   • US 13/008,279  -  TW I432730
   • 發明人：沈哲鯤、陳芮琳、周祐吉
2. Novel Compounds for Therapy of β-Thalassemia and Sickle Cell Disease.
   • US 8,822,491  -  EP (France) 2678339  -  CN ZL201280009511.9  -  TW I466,670
   • 發明人：沈哲鯤、周祐吉
3. Methods and Compositions for Treating β-Thalassemia and Sickle Cell Disease.
   • US 9,662,324  -  TW I536,993  -  TW I576,339  -  CN ZL2013800638764
   • 發明人：沈哲鯤、蘇燦隆、周祐吉
4. Immunoconjugate and Uses Thereof
   • US 10562976B2
   • 發明人：楊安綏、郭蔚瑩、許鴻儒、陳鴻森、周祐吉、鄒岳良、彭洪斌、簡智偉、余忠銘、邱奕凱、陳英謙、董昭萍、蕭宏昇、王惠鈞